Competing risk nomogram for predicting cancer-specific survival in patients with primary bone diffuse large B-cell lymphoma: a SEER-based retrospective study.

Background: Cardiovascular death (CVD) represents a significant determinant affecting the long-term survival outcomes of cancer patients, independent of primary tumor effects. Consequently, this study aims to identify prognostic factors in patients with primary bone diffuse large B-cell lymphoma (PB-DLBCL) using CVD as a competing risk and to develop a competing risk nomogram. Methods: Data for patients diagnosed with PB-DLBCL from 2000 to 2015 were sourced from the Surveillance Epidemiology, and End Results (SEER) database and a total of 1,224 PB-DLBCL patients were eventually included in this study. The approach of multiple imputation is utilized to address the issue of missing data. Univariate Cox regression analysis and the best subset selection method are utilized for variable screening, from which overlapping independent risk factors are identified for subsequent multivariate Cox analysis and multivariate competing risk analysis. The Fine-Gray test was applied for univariate competing risk analysis. Significant variables from the multivariate competing risk analysis were selected as independent prognostic factors to construct a competing risk nomogram for predicting 1-, 5-, and 10-year cancer-specific survival (CSS). The model's performance was evaluated by Harrell concordance index (C-index), time-dependent receiver operating characteristic (ROC) curves, and calibration curves. Results: Compared with the competing risk model, the conventional Cox regression model overestimates the impact of variables on the incidence of cancer-specific death (CSD). Age, income, B symptoms, Ann Arbor stage, primary site, laterality, chemotherapy, and systemic therapy were identified as independent risk factors for CSD. A competing risk nomogram was developed incorporating these variables to predict CSS. In the training set, the areas under the curve (AUC) for 1-, 5-, and 10-year CSS were 0.879, 0.848, and 0.839, respectively, while in the testing set, the AUC values were 0.794, 0.781, and 0.790, respectively. The C-index of the model was 0.853, 0.823, and 0.819 for 1-, 5-, and 10-year survival in the training set, and 0.777, 0.757, and 0.754 in the testing set. The calibration curve indicated favorable consistency for the competing risk nomogram. Conclusions: The competing risk nomogram was effectively utilized to predict CSS in patients with PB-DLBCL It exhibited robust predictive performance and holds potential for enhancing treatment decision-making in clinical practice.